Advertisement

Drugs

, Volume 55, Issue 5, pp 645–674 | Cite as

An Overview of Topical Antifungal Therapy in Dermatomycoses

A North American Perspective
  • Aditya K. Gupta
  • Thomas R. Einarson
  • Richard C. Summerbell
  • Neil H. Shear
Review Article

Summary

Dermatophytes cause fungal infections of keratinised tissues, e.g. skin, hair and nails. The organisms belong to 3 genera, Trichophyton, Epidermophyton and Microsporum. Dermatophytes may be grouped into 3 categories based on host preference and natural habitat. Anthropophilic species predominantly infect humans, geophilic species are soil based and may infect both humans and animals, zoophilic species generally infect non-human mammals.

It is important to confirm mycologically the clinical diagnosis of onychomycosis and other tinea infections prior to commencing therapy. The identity of the fungal organism may provide guidance about the appropriateness of a given topical antifungal agent. Special techniques may be required to obtain the best yield of fungal organisms from a given site, especially the scalp and nails.

It is also important to realise the limitations of certain diagnostic aids e.g., Wood’s light examination is positive in tinea capitis due to M. canis and M. audouinii (ectothrix organisms); however, Wood’s light examination is negative in T. tonsurans (endothrix organism). Similarly, it is important to be aware that cicloheximide in culture medium will inhibit growth of non-dermatophytes. Appropriate media are therefore required to evaluate the growth of some significant non-dermatophyte moulds.

For tinea infections other than tinea capitis and tinea unguium, topical antifungals may be considered. For effective therapy of tinea capitis an oral antifungal is generally necessary. Similarly, oral antifungals are the therapy of choice, especially if onychomycosis is moderate to severe. Furthermore, where the tinea infection involves a large area, in an immunocompromised host or if infection is recurrent with poor response to topical agents, then oral antifungal therapy may be necessary.

Topical antifungal agents may be broadly divided into specific and nonspecific agents. The former group includes the polyenes, azoles, allylamines, amorolfine, ciclopirox and butenafine. Generally the topical agent is available as a cream, sometimes for use intravaginally. Less commonly, the formulation may be in the form of a powder, lacquer, spray, gel or solution. Many of these agents have a broad spectrum of activity, being effective against dermatophytes, yeasts and Malassezia furfur. For the treatment of tinea corporis, tinea cruris tinea versicolor and cutaneous candidosis, once or twice daily application may be required, the most common duration of therapy being 2 to 4 weeks. For tinea pedis the most common treatment duration is 4 to 6 weeks.

Keywords

Terbinafine Tinea Capitis Tinea Pedis Econazole Ciclopirox 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weitzman I, Summerbell, RC. The dermatophytes. Clin Microbiol Rev 1995; 8: 240–59PubMedGoogle Scholar
  2. 2.
    Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994; 31: S21–5PubMedCrossRefGoogle Scholar
  3. 3.
    Weitzman I, Kane J. Dermatophytes and agents of superficial mycoses. In: Hausler WJ, Herrmann KL, Isenberg HD, et al., editors. Manual of clinical microbiology. 5th ed. New York: American Society for Microbiology, 1991: 601–6Google Scholar
  4. 4.
    Del Cas E, Vernes A. Parasitic adaptation of pathogenic fungi to mammalian hosts. Crit Rev Microbiol 1986; 13: 173–218CrossRefGoogle Scholar
  5. 5.
    King RD, Khan HA, Foye JC, et al. Transferrin, iron and dermatophytes:1.Serum dermatophyte inhibitory component definitively identified as unsaturated transferrin. J Lab Clin Med 1975; 86: 204–12PubMedGoogle Scholar
  6. 6.
    Novick NL, Tapia L, Bottone EJ. Invasive Trichophyton rubrum infection in an immunocompromised host. Am J Med 1987; 82: 321–5PubMedCrossRefGoogle Scholar
  7. 7.
    Elewski BE, Sullivan J. Dermatophytes as opportunisitc pathogens. J Am Acad Dermatol 1994; 30: 1021–2PubMedCrossRefGoogle Scholar
  8. 8.
    Grossman ME, Pappert AS, Garzon MC, et al. Invasive Trichophyton rubrum infection in the immunocompromised host: report of three cases. J Am Acad Dermatol 1995; 33: 315–8PubMedCrossRefGoogle Scholar
  9. 9.
    Faergemann J, Gisslen H, Dahlberg E, et al. Trichophyton rubrum abcesses in immunocompromised patients. Acta Derm Venereol (Stockh) 1989; 69: 244–7Google Scholar
  10. 10.
    Lestringant GG, Lindley SK, Hillsdon-Smith J, et al. Deep dermatophytosis to T rubrum and T verrucosum in an immunosuppressed patient. Int J Dermatol 1988; 27: 707–9PubMedCrossRefGoogle Scholar
  11. 11.
    Tsang P, Hopkins T, Jimenez-Lucho V. Deep dermatophytosis caused by Trichophyton rubrum in a patient with AIDS. J Am Acad Dermatol 1996; 34(6): 1090–1PubMedCrossRefGoogle Scholar
  12. 12.
    Weitzman I, McGinnis MR, Padhye AA, et al. The genus Arthroderma and its later synonym Nannizzia. Mycotaxon 1986; 25: 505–18Google Scholar
  13. 13.
    Currah RS. Taxonomy of the Onygenales: Arthrodermataceae, Gymnoascaceae, Myxotrichaceae, and Onygenaceae. Mycotaxon 1985; 24: 1–216Google Scholar
  14. 14.
    Stern RS. The epidemiology of cutaneous disease. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., editors. Dermatology in general practice. New York: McGraw Hill, 1993: 7–13Google Scholar
  15. 15.
    Anonymous. Prevalence, morbidity, and cost of dermatological diseases. J Invest Dermatol 1979; 73: 395–401Google Scholar
  16. 16.
    Anonymous. Infections. J Invest Dermatol 1979; 73: 452–9CrossRefGoogle Scholar
  17. 17.
    Ajello L. Geographic distribution and prevalence of the dermatophytes. Ann NY Acad Sci 1960; 89: 30–8PubMedCrossRefGoogle Scholar
  18. 18.
    Katoh T, Sano T, Kagawa S. Isolations of dermatophyte from clinically normal scalps in M. canis infections using the hairbrush method. Mycopathologia 1990; 112: 23–5PubMedCrossRefGoogle Scholar
  19. 19.
    Klokke AH, Purushotham AG, Sundaraju D. Mass treatment of non-fluorescent tinea capitis in an orphanage in India: trial with a low griseofulvin dose using a modified brush-sampling technique. Trop Geogr Med 1966; 18: 305–9PubMedGoogle Scholar
  20. 20.
    Mackenzie DWR. ’Hairbrush diagnosis’ in detection and eradication of non-flourescent scalp ringworm. BMJ 1963; 2: 363–5PubMedCrossRefGoogle Scholar
  21. 21.
    Hubbard TW, de Triquet JM. Brush-culture method for diagnosing tinea capitis. Pediatrics 1992; 90: 416–8PubMedGoogle Scholar
  22. 22.
    Rasmussen JE. Cutaneous fungus infections in children. Pediatr Rev 1992; 13: 152–6PubMedCrossRefGoogle Scholar
  23. 23.
    Davey KG, Campbell OK, Warnock DW Mycological techniques. J Clin Pathol 1996; 49: 95–9PubMedCrossRefGoogle Scholar
  24. 24.
    Suarez SM, Silvers DN, Scher RK, et al. Histologic evaluation of nail clippings for diagnosing onychomycosis. Arch Dermatol 1991; 127: 1517–9PubMedCrossRefGoogle Scholar
  25. 25.
    Daniel CR III. The diagnosis of nail fungal infection. Arch Dermatol 1991; 127: 1566–7PubMedCrossRefGoogle Scholar
  26. 26.
    Gupta AK, Scher RK, De Doncker P. Current management of onychomycosis: an overview. Dermatol Clin 1997; 15: 121–35PubMedCrossRefGoogle Scholar
  27. 27.
    Zaias N, Taplin D. Improved preparation for the diagnosis of mycologic diseases. Arch Dermatol 1966; 93: 608–9PubMedCrossRefGoogle Scholar
  28. 28.
    Elewski BE. Clinical pearl: diagnosis of onychomycosis. J Am Acad Dermatol 1995; 32: 500–1PubMedCrossRefGoogle Scholar
  29. 29.
    Robinson BE, Padhye AA. Collection, transport and processing of clinical specimens. In: Wentworth BB, editor. Diagnostic procedures for mycotic and parasitic infections. Washington, DC: American Public Health Association, 1988: 11–32Google Scholar
  30. 30.
    Taplin D, Zaias N, Rebell G, et al. Isolation and recognition of dermatophytes on a new medium (DTM). Arch Dermatol 1969; 99: 203–9PubMedCrossRefGoogle Scholar
  31. 31.
    Rebell G, Taplin D. Dermatophytes, their recognition and identification. Coral Gables (FL): University of Miami Press, 1970Google Scholar
  32. 32.
    Fischer JB, Kane J. The laboratory diagnosis of dermatophytosis complicated with Candida albicans. Can J Microbiol 1974; 20: 167–82CrossRefGoogle Scholar
  33. 33.
    Kligman AM, Mescon H, deLamater ED. The Hotchkiss-Mcmanus stain for the histopathologic diagnosis of fungus disease. Am J Clin Pathol 1951; 21: 86–91PubMedGoogle Scholar
  34. 34.
    Piérard GE, Arrese JE, De Doncker P, et al. Present and potential diagnostic techniques in onychomycosis. J Am Acad Dermatol 1996; 34: 273–7PubMedCrossRefGoogle Scholar
  35. 35.
    Calderone RA. Immunoregulation of dermatophytosis. Crit Rev Microbiol 1989; 16: 338–68CrossRefGoogle Scholar
  36. 36.
    Jones H. Immune response and host resistance of humans to dermatophyte infection. J Am Acad Dermatol 1993; 28: sl2–8Google Scholar
  37. 37.
    Blake JS, Dahl MV, Herron MJ, et al. An immunoinhibitory cell wall glycoprotein (Mannan) from Trichophyton rubrum. J Invest Dermatol 1991; 96: 657–61PubMedCrossRefGoogle Scholar
  38. 38.
    Hay RJ. Chronic dermatophyte infections: I. Clinical and mycological features. Br J Dermatol 1982; 106: 1–7Google Scholar
  39. 39.
    Dahl MV. Suppression of immunity and inflammation by products produced by dermatophytes. J Am Acad Dermatol 1993; 28: S19–23PubMedCrossRefGoogle Scholar
  40. 40.
    Sharma V, Hall JC, Knapp JF, et al. Scalp colonization by Trichophyton tonsurans in an urban pediatric clinic. Arch Dermatol 1988; 124: 1511–3PubMedCrossRefGoogle Scholar
  41. 41.
    Babel DE, Baughman SA. Evaluation of the adult carrier state in juvenile tinea capitis caused by trichophyton. J Am Acad Dermatol 1989; 21: 1209–12PubMedCrossRefGoogle Scholar
  42. 42.
    Shah PC, Krajden S, Kane J, et al. Tinea corporis caused by Microsporum canis: report of a nosocomial outbreak. Eur J Epidemiol 1988; 4: 33–8PubMedCrossRefGoogle Scholar
  43. 43.
    Snider R, Landers S, Levy ML. The ringworm riddle: an outbreak of Microsporum canis in the nursery. Ped Infect Dis J 1993; 12: 145–8CrossRefGoogle Scholar
  44. 44.
    Sulzberger MB, Baer RL. Some recent advances in dermatological mycology. In: Sulzberger MB, Baer RL, editors. Year book of dermatology and syphilology. Chicago: Year Book Publishers, 1955: 7–33Google Scholar
  45. 45.
    Taplin D. Superficial mycoses. J Invest Dermatol 1976; 67: 177–81PubMedCrossRefGoogle Scholar
  46. 46.
    Jones HE. Ketoconazole in the management of fungal disease. In: Levine HB, editor. Current therapies for mycotic diseases. Auckland: ADIS Press, 1982: 14–24Google Scholar
  47. 47.
    Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview: part I. J Am Acad Dermatol 1994; 30: 677–98PubMedCrossRefGoogle Scholar
  48. 48.
    Degreef H. The treatment of superficial skin infections caused by dermatophytes. Curr Top Med Mycol 1992; 4: 189–206PubMedCrossRefGoogle Scholar
  49. 49.
    Rogers SCF, Burrows D, Neill D. Percutaneous absorption of phenol and methyl alcohol in magenta paint B.P.C. Br J Dermatol 1978; 98: 559–60PubMedCrossRefGoogle Scholar
  50. 50.
    Fisher DA. Castellani’s paint. Arch Dermatol 1979; 115: 675PubMedCrossRefGoogle Scholar
  51. 51.
    Hay RJ. The current status of antimycotics in the treatment of local mycoses. Acta Derm Venereol (Stockh) 1986; 121: 103–8Google Scholar
  52. 52.
    Arnold HL. Castellani’s paint without fuchsin. Arch Dermatol 1979; 115: 1287PubMedCrossRefGoogle Scholar
  53. 53.
    Fisher AA. Irritant and toxic reactions to phenol in topical medications. Cutis 1980; 26: 363–4PubMedGoogle Scholar
  54. 54.
    Leyden JJ, Kligman AM. Aluminum chloride in the treatment of symptomatic athlete’s foot. Arch Dermatol 1975; 111: 1004–10PubMedCrossRefGoogle Scholar
  55. 55.
    Chren M-M, Bickers DR. Dermatological pharmacology. In: Gilman AG, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. US: McGraw-Hill, 1993: 1572–91Google Scholar
  56. 56.
    Smith EB, Powell RF, Graham JL, et al. Topical undecylenic acid in tinea pedis: a new look. Int J Dermatol 1977; 16: 52–6PubMedCrossRefGoogle Scholar
  57. 57.
    Lyddon FE, Gundersen K, Maibach HI. Short chain fatty acids in the treatment of dermatophytoses. Int JDermatol 1980; 19: 24–8CrossRefGoogle Scholar
  58. 58.
    Bennett JE. Antimicrobial agents. Antifungal agents. In: Gilman AG, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. US: McGraw-Hill, 1993: 1165–81Google Scholar
  59. 59.
    Hernanz ADP, Vicente SD, Ramos FM, et al. Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev Infect Dis 1987; 9: S121–7CrossRefGoogle Scholar
  60. 60.
    Hersle K. Selenium sulphide treatment of tinea versicolor. Acta Derm Venereol (Stockh) 1971; 51: 476–8Google Scholar
  61. 61.
    Albright SD, Hitch JM. Rapid treatment of tinea versicolor with selenium sulfide. Arch Dermatol 1966; 93: 460–2PubMedCrossRefGoogle Scholar
  62. 62.
    Sánchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol 1984; 11(2): 235–7PubMedCrossRefGoogle Scholar
  63. 63.
    Danby FW, Maddin WS, Margesson LJ, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29: 1008–12PubMedCrossRefGoogle Scholar
  64. 64.
    Sánchez JL, Torres VM. Selenium sulfide in tinea versicolor: blood and urine levels. J Am Acad Dermatol 1984; 11: 238–41PubMedCrossRefGoogle Scholar
  65. 65.
    Ketoconazole shampoo for dandruff [editorial].Med Lett Drugs Ther 1994; 36: 68Google Scholar
  66. 66.
    Allen HB, Honig PJ, Leyden JJ, et al. Selenium sulfide: adjunctive therapy for tinea capitis. Pediatrics 1982; 69: 81–3PubMedGoogle Scholar
  67. 67.
    Brauer EW, Opdyke DL, Burnett CM. The antiseborrheic qualities of zinc pyrithione (zinc pyridine-2-thiol-l-oxide) in a cream vehicle. J Invest Dermatol 1966; 47: 174PubMedGoogle Scholar
  68. 68.
    Brauer EW. Antiseborrheic qualities of zinc pyrithione in a cream vehicle: III. Clinical experience in pityriasis capitis (dandruff, seborrheic dermatitis of the scalp). Cutis 1969; 5: 723Google Scholar
  69. 69.
    Faergemann J, Fredriksson T. An open trial of the effect of a zinc pyrithione shampoo in tinea versicolor. Cutis 1980; 25: 667, 669PubMedGoogle Scholar
  70. 70.
    Fredriksson T, Faergemann J. Double-blind comparison of a zinc pyrithione shampoo and its shampoo base in the treatment of tinea versicolor. Cutis 1981; 31: 436–7Google Scholar
  71. 71.
    Tinver lotion and other topical preparations for tinea versicolor [editorial]. Med Lett 1965: 74–5Google Scholar
  72. 72.
    Manna VK, Pearse AD, Marks R. The effect of povidone-iodine paint on fungal infection. J Int Med Res 1984; 12: 121–3PubMedGoogle Scholar
  73. 73.
    Bamford JTM. Treatment of tinea versicolor with sulfur-salicylic shampoo. J Am Acad Dermatol 1983; 8: 211–3PubMedCrossRefGoogle Scholar
  74. 74.
    Bamford JTM. Tinea versicolor treatment. Arch Dermatol 1974; 110: 956PubMedCrossRefGoogle Scholar
  75. 75.
    Montes LF, Oakes RA, Pert P, et al. Topical griseofulvin in tinea versicolor: a double-blind study. J Am Acad Dermatol 1991; 25(4): 726–8PubMedCrossRefGoogle Scholar
  76. 76.
    Prestia AE. Topical benzoyl peroxide for the treatment of tinea versicolor. J Am Acad Dermatol 1983; 9: 277–8PubMedCrossRefGoogle Scholar
  77. 77.
    Mills OH, Kligman AM. Tretinoin in tinea versicolor. Arch Dermatol 1974; 110: 638PubMedCrossRefGoogle Scholar
  78. 78.
    Faergemann J, Fredriksson T. Propylene glycol in the treatment of tinea versicolor. Acta Derm Venereol (Stockh) 1979; 60: 92–3Google Scholar
  79. 79.
    Goldsmith LA. Propylene glycol. Int J Dermatol 1978; 17: 703–5PubMedGoogle Scholar
  80. 80.
    Faergemann J, Swanbeck G. Treatment of onychomycosis with a propylene glycol-urea-lactic acid solution. Mycoses 1988; 32: 526–40Google Scholar
  81. 81.
    Kligman AM. Dermatologic uses of urea. Acta Derm Venereol (Stockh) 1957; 37: 155Google Scholar
  82. 82.
    Swanbeck G. A new treatment of ichthyosis and other hyperkeratotic conditions. Acta Derm Venereol (Stockh) 1970; 48: 123Google Scholar
  83. 83.
    Ashton H, Frenk E, Stevenson CJ. Urea as a topical agent. Br J Dermatol 1970; 84: 194CrossRefGoogle Scholar
  84. 84.
    Kuntz TDJ, Brassfield TS. Hydration of macromolecules: II. Effects of urea on protein hydration. Arch Biochem Biophys 1971; 142: 660Google Scholar
  85. 85.
    Grice K, Sattar H, Baker H. Urea and retinoic acid in ichthyosis and their effect on transepidermal water loss and water holding capacity of stratum corneum. Acta Derm Venereol (Stockh) 1973; 53: 114Google Scholar
  86. 86.
    Farber EM, South DA. Urea ointment in the nonsurgical avulsion of nail dystrophies. Cutis 1978; 22: 689–92PubMedGoogle Scholar
  87. 87.
    South DA, Farber EM. Urea ointment in the nonsurgical avulsion of nail dystrophies — a reappraisal. Cutis 1980; 25: 609–12PubMedGoogle Scholar
  88. 88.
    Buselmeier TJ. Combination urea and salicylic acid ointment nail avulsion in nondystrophic nails: a follow-up observation. Cutis 1980; 25: 397–405PubMedGoogle Scholar
  89. 89.
    Hay RJ, Roberts DT, Doherty VR, et al. The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 1988; 13: 164–7PubMedCrossRefGoogle Scholar
  90. 90.
    Hardjoko FS, Widyanto S, Singgih I, et al. Treatment of onychomycosis with a bifonazole-urea combination. Mycoses 1990; 33: 167–71PubMedGoogle Scholar
  91. 91.
    Torres-Rodriguez JM, Madrenys N, Nicolás MC. Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole. Mycoses 1991; 34: 499–504PubMedCrossRefGoogle Scholar
  92. 92.
    Roberts DT, Hay RJ, Doherty VR, et al. Topical treatment of onychomycosis using bifonazole 1%/urea 40% paste. Ann NY Acad Sci: 586–7Google Scholar
  93. 93.
    Nolting S. Non-traumatic removal of the nail and simultaneous treatment of onychomycosis. Dermatologica 1984; 169: 117–20PubMedCrossRefGoogle Scholar
  94. 94.
    Bonifaz A, Guzman A, Garcia C, et al. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Int J Dermatol 1995; 34(7): 500–3PubMedCrossRefGoogle Scholar
  95. 95.
    Ishii M, Hamada T, Asai Y. Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment. Dermatologica 1983; 167: 273–9PubMedCrossRefGoogle Scholar
  96. 96.
    White MI, Clayton YM. The treatment of fungus and yeast infections of nails by the method of chemical removal. Clin Exp Dermatol 1982; 7: 273–6PubMedCrossRefGoogle Scholar
  97. 97.
    Rollman O. Treatment of onychomycosis by partial nail avulsion and topical miconazole. Dermatologica 1982; 165: 54–61PubMedCrossRefGoogle Scholar
  98. 98.
    Ramadan W, Mourad B, Ibrahim S, et al. Oil of bitter orange: new topical antifungal agent. Int J Dermatol 1996; 35: 448–9PubMedCrossRefGoogle Scholar
  99. 99.
    Budavari S. Oil of bitter orange. In: Budavari S, Maryadele J, Ann S, et al., editors. The Merck Index: an encyclopedia of chemicals, drugs, and biologicals. 11th ed. Rahway (NJ): Merck and Co., Inc, 1989: 1072–8Google Scholar
  100. 100.
    Oxford AE, Raistrick H, Simonant P. Studies in the biochemistry of micro-organism LX. Griseofulvin C18H17O6Cl, a metabolic product of Penicillium griseofulvin Dierck. Biochem J 1939; 33: 240PubMedGoogle Scholar
  101. 101.
    Gentles JC. Experimental ring-worm in guinea pigs: oral treatment with griseofulvin. Nature 1958; 182: 476PubMedCrossRefGoogle Scholar
  102. 102.
    Blank H, Roth FJJ. The treatment of dermatomycoses with orally administered griseofulvin. Arch Dermatol 1959; 79: 259CrossRefGoogle Scholar
  103. 103.
    Blank H. Commentary: treatment of dermatomycoses with griseofulvin. Arch Dermatol 1982; 118: 835–6CrossRefGoogle Scholar
  104. 104.
    Korting HC, Schäfer-Korting M. Is tinea unguium still widely incurable? Arch Dermatol 1992; 128: 243–8PubMedCrossRefGoogle Scholar
  105. 105.
    Martin AR. The systematic and local treatment of experimental dermatophytosis with griseofulvin. J Invest Dermatol 1959; 32: 525PubMedCrossRefGoogle Scholar
  106. 106.
    Goldman L, Preston RH, Schwarz J. Topical griseofulvin therapy of that which is called tinea pedia. Acta Derm Venereol (Stockh) 1959; 39: 454–60Google Scholar
  107. 107.
    Höfer W, Hönemann W, Koch E. Zur behandlung der Dermato-mykosen mit Gricin-Salbe. Dtsch Gesundheitw 1968; 23: 1370Google Scholar
  108. 108.
    Wozniak KD, Friedrich E, Janik G. Griseofulvin-Salbende-handlung superficiller Trichophytien. Mykosen 1970; 13: 427PubMedCrossRefGoogle Scholar
  109. 109.
    Arievich AM, Ziserman VE. Experience of topical application of griseofulvin for treatment of some mycotic lesions of the skin. Vestn Dermatol Venerol 1972; 46: 82PubMedGoogle Scholar
  110. 110.
    Levine HB, Cobb JM, Friedman RH. Griseofulvin in DMSO, penetration into guinea-pig skin and clinical findings in feline ringworm. Sabouraudia 1971; 9: 43PubMedCrossRefGoogle Scholar
  111. 111.
    Stoughton RB, Fritsch W. Influence of dimethylsulphoxide (DMSO) on human percutaneous absorption. Arch Dermatol 1964; 90: 512PubMedCrossRefGoogle Scholar
  112. 112.
    Munro DD, Stoughton RB. Dimethylacetamide (DMAC) and dimethylformamide (DMFA) effect on percutaneous absorption. Arch Dermatol 1965; 92: 585PubMedCrossRefGoogle Scholar
  113. 113.
    Knight AG. The activity of various topical griseofulvin preparations and the appearance of oral griseofulvin in the stratum corneum. Br J Dermatol 1974; 91: 49–55PubMedCrossRefGoogle Scholar
  114. 114.
    Abdel-Aal H, El-Shazli M, Saleh AM. Topically applied griseofulvin in the treatment of superficial dermatomycoses in Egypt. J Int Med Res 1977; 5: 382PubMedGoogle Scholar
  115. 115.
    Macasaet EN, Pert P. Topical (1%) solution of griseofulvin in the treatment of tinea corporis. Br J Dermatol 1991; 124: 110–1PubMedCrossRefGoogle Scholar
  116. 116.
    Zarowny DP, Rogers RS, Tindall JR Evaluation of the effectiveness of griseofulvin, tolnaftate and placebo in the topical therapy of superficial dermatophytoses. J Invest Dermatol 1975; 64: 268–72PubMedCrossRefGoogle Scholar
  117. 117.
    Epstein WL, Shah VP, Jones HE, et al. Topically applied griseofulvin in prevention and treatment of Trichophyton mentagrophytes. Arch Dermatol 1975; 111: 1293–7PubMedCrossRefGoogle Scholar
  118. 118.
    Wallace SM, Shah VP, Epstein WL, et al. Topically applied antifungal agents: percutaneous penetration and prophylactic activity against Trichophyton. mentagrophytes infection. Arch Dermatol 1977; 113: 1539–42PubMedCrossRefGoogle Scholar
  119. 119.
    Aly R, Bayles CI, Oakes RA, et al. Topical griseofulvin in the treatment of dermatophytes. Clin Exp Dermatol 1994; 19: 43–6PubMedCrossRefGoogle Scholar
  120. 120.
    Montes LF, Oakes RA, Pert P, et al. Topical griseofulvin in tinea versicolor: a double-blind study. J Am Acad Dermatol 1991; 25: 726–8PubMedCrossRefGoogle Scholar
  121. 121.
    Dunne M, Flood M, Herxheimer A. Clioquinol: availability and instructions for use. J Antimicrob Chemother 1976; 2: 21–9PubMedCrossRefGoogle Scholar
  122. 122.
    Clifford Rose F, Gawel M. Clioquinol neurotoxicity: an overview. Acta Neurol Scand 1984; 70: 137–45Google Scholar
  123. 123.
    Traveler’s warning: entero-vioform [editorial]. Med Lett Drugs Ther 1975; 17: 105–6Google Scholar
  124. 124.
    Stohs SJ, Ezzedeen FW, Anderson AK. Percutananeous absorption of iodochlorhydroxyquin in humans. J Invest Dermatol 1984; 82: 195–8PubMedCrossRefGoogle Scholar
  125. 125.
    Fischer I, Hartvig P. Skin absorption of 8-hydroxyquinolines. Lancet 1977; I: 603CrossRefGoogle Scholar
  126. 126.
    Bickers DR, Hazen PG, Lynch WS. Antifungal and antiyeast agents. In: Azarnoff DL, editor. Clinical pharmacology of skin disease. New York: Churchill Livingstone, 1984: 163–88Google Scholar
  127. 127.
    Battistini F, Bolivar C, Zaias N, et al. Clinical antifungal activity of thiabendazole. Arch Dermatol 1974; 109: 695–9PubMedCrossRefGoogle Scholar
  128. 128.
    Robinson HJ, Phares HF, Graessle OE. Antimycotic properties of thiabendazole. J Invest Dermatol 1964; 42: 479–81PubMedCrossRefGoogle Scholar
  129. 129.
    Blank H, Rebell G. Thiabendazole activity against the fungi of dermatophytosis, mycetoma and chromomycosis. J Invest Dermatol 1965; 44: 219–20PubMedGoogle Scholar
  130. 130.
    Sorensen LJ, Robinson HJ. Activity of thiabendazole against Trichophyton mentagrophytes in guinea pigs. Antimicrob Agents Chemother 1964; 4: 742–5Google Scholar
  131. 131.
    Stone OJ, Ritchie EB, Willis CJ. Thiabendazole in dimethyl sulfoxide for tinea nigra palmaris. Arch Dermatol 1966; 93: 241–2PubMedCrossRefGoogle Scholar
  132. 132.
    Noguchi T, Kaji A, Igarashi Y, et al. Antitrichophyton activity of naphthiomates. Antimicrob Agents Chemother 1962: 259–67Google Scholar
  133. 133.
    Ryder NS, Frank I, Dupont M-C. Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate. Antimicrob Agents Chemother 1986; 29: 858–60PubMedCrossRefGoogle Scholar
  134. 134.
    Barrett-Bee KJ, Lane AC, Turner RW The mode of antifungal action of tolnaftate. J Med Vet Mycol 1986; 24: 155–60PubMedCrossRefGoogle Scholar
  135. 135.
    Robinson HM, Raskin J. Tolnaftate, a potent topical antifungal agent. Arch Dermatol 1965; 91: 372–6CrossRefGoogle Scholar
  136. 136.
    Weinstein MJ, Oden EM, Moss E. Antifungal properites of tolnaftate in vitro and in vivo. Antimicrob Agents Chemother 1964; 3: 595–601Google Scholar
  137. 137.
    Roberts SOB, Champion RH. Treatment of ringworm infections with tolnaftate ointment. Practitioner 1967; 199: 797–8Google Scholar
  138. 138.
    Alban J. Tolnaftate in superficial fungus infections. Am J Dis Child 1965; 110: 624–7PubMedGoogle Scholar
  139. 139.
    Gomez EC, Huntley AC, Isseroff R, et al. Efficacy of tolciclate solution in patients with tinea pedis. Clin Ther 1986; 8(6): 694–9PubMedGoogle Scholar
  140. 140.
    Cuce LC, Contijo Assuncao BF, Medawar LG, et al. Tolciclate versus miconazole, a double-blind trial in patients with dermatomycosis. J Int Med Res 1980; 8: 144–7PubMedGoogle Scholar
  141. 141.
    de Carneri I, Monti G, Bianchi A, et al. Tolciclate against dermatophytes. Arzneimittel Forschung 1976; 26: 769–72PubMedGoogle Scholar
  142. 142.
    Hermann HW. Clinical efficacy studies of haloprogin, a new topical antimicrobial agent. Arch Dermatol 1972; 106: 839–42PubMedCrossRefGoogle Scholar
  143. 143.
    Carter VH. A controlled study of haloprogin and tolnaftate in tinea pedis. Curr Ther Res 1972; 14: 307–10PubMedGoogle Scholar
  144. 144.
    Katz R, Cahn B. Haloprogin therapy for dermatophyte infections. Arch Dermatol 1972; 106: 837–8PubMedCrossRefGoogle Scholar
  145. 145.
    VanDersarl JV, Sheppard RH. Clotrimazole vs haloprogin treatment of tinea cruris. Arch Dermatol 1977; 113: 1233–5PubMedCrossRefGoogle Scholar
  146. 146.
    Clayton YM, Gange RW, Macdonald DM, et al. A clinical double-blind trial of topical haloprogin and miconazole against superficial fungal infections. Clin Exp Dermatol 1979; 4: 65–73PubMedCrossRefGoogle Scholar
  147. 147.
    Carter VH, Olansky S. Haloprogin and nystatin therapy for cutaneous candidiasis. Arch Dermatol 1974; 110: 81–2PubMedCrossRefGoogle Scholar
  148. 148.
    Rudolph RI. Allergic contact dermatitis caused by haloprogin. Arch Dermatol 1975; 111: 1487–8PubMedCrossRefGoogle Scholar
  149. 149.
    Moss HV Allergic contact dermatitis due to halotex solution. Arch Dermatol 1974; 109: 572PubMedCrossRefGoogle Scholar
  150. 150.
    Berlin AR, Miller OF. Allergic contact dermatitis from ethyl sebacate in haloprogin cream. Arch Dermatol 1976; 112: 1563–4PubMedCrossRefGoogle Scholar
  151. 151.
    Medoff G, Kobayashi GA. The polyenes. In: Speller DCE, editior. Antifungal chemotherapy. Chichester: John Wiley & Sons, 1980: 3–33Google Scholar
  152. 152.
    Hazen EL, Brown R. Two antifungal agents produced by a soil actinomycete. Science 1950; 112: 423PubMedGoogle Scholar
  153. 153.
    Hazen EL, Brown R. Nystatin. Ann NY Acad Sci 1960; 89: 258–66PubMedCrossRefGoogle Scholar
  154. 154.
    Dixon PN, Warin RP, English MR Alimentary Candida albicans and napkin rashes. Br J Dermatol 1972; 86: 458–62PubMedCrossRefGoogle Scholar
  155. 155.
    Coskey RJ. Contact dermatitis due to nystatin. Arch Dermatol 1971; 103: 228PubMedCrossRefGoogle Scholar
  156. 156.
    Wasilewski C. Allergic contact dermatitis from nystatin. Arch Dermatol 1970; 102: 216–7PubMedCrossRefGoogle Scholar
  157. 157.
    de Groot A, Conemans JMH. Nystatin allergy: petrolatum is not the optimal vehicle for patch testing. Dermatol Clin 1990; 8: 153–5PubMedGoogle Scholar
  158. 158.
    Natamycin for keratomycosis [editorial]. Med Lett Drugs Ther 1979; 21: 79–80Google Scholar
  159. 159.
    Abrams BB, Hänel H, Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin Dermatol 1991; 9: 471–7PubMedCrossRefGoogle Scholar
  160. 160.
    Abruzzo GK, Fromtling RA, Turnbull TA. Effects of bifonazole, fluconazole, itraconazole, and terbinafine on the chemiluminescence response of immune cells. J Antimicrob Chemother 1987; 20: 61–8PubMedCrossRefGoogle Scholar
  161. 161.
    Kligman AM, Bogaert H, Cordero C, et al. Evaluation of cicloprox olamine cream for the treatment of tinea pedis: multicenter, double-blind comparative studies. Clin Ther 1985; 7: 409–17Google Scholar
  162. 162.
    Aly R, Bagatell FK, Dittmar W, et al. Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis. Clin Ther 1989; 11: 290–303PubMedGoogle Scholar
  163. 163.
    Bogaert H, Cordero C, Ollague W, et al. Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. J Int Med Res 1986; 14: 210–6PubMedGoogle Scholar
  164. 164.
    Lassus A, Nolting KS, Savopoulos C. Comparison of cicloprox olamine 1% cream with cicloprox 1%-hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses. Clin Ther 1988; 10: 594–9PubMedGoogle Scholar
  165. 165.
    Cullen SI, Frost P, Jacobson C, et al. Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Clin Ther 1985; 7: 574–83Google Scholar
  166. 166.
    Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream: a preliminary review of its antimicrobial activity and therapeutic use. Drugs 1985; 29: 330–41PubMedCrossRefGoogle Scholar
  167. 167.
    Bagatell FK, Bogaert H, Cullen SI, et al. Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. Clin Ther 1985; 8: 41–8Google Scholar
  168. 168.
    Altmeyer P, Nolting S, Kuhlwein A, et al. Effect of fenticonazole spray in cutaneous mycosis: a double-blind clinical trial versus ciclopiroxolamine spray. J Int Med Res 1990; 18: 61–7PubMedGoogle Scholar
  169. 169.
    Corte M, Jung K, Linker U, et al. Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor. Mycoses 1989; 32: 200–3PubMedCrossRefGoogle Scholar
  170. 170.
    Ceschin-Roques CG, Hanel H, Pruja-Bougaret SM, et al. Ciclopiroxolamine nail lacquer 8%: in vitro penetration through nails and in. vitro effect on pig skin. Skin Pharmacol 1991; 4: 89–94PubMedCrossRefGoogle Scholar
  171. 171.
    BaranR,VirabenR,Bougaret S,et al.Effect of an 8%ciclopirox antifungal lacquer in onychomycosis: a multicenter, double-blind clinical trial versus systemic ketoconazole [abstract]. Second Congress of the European Academy of Dermatology and Venereology; 1991: Athens, 182Google Scholar
  172. 172.
    Ulbricht H, Wörz K. Therapy of onychomycosis due to moulds with ciclopirox nail lacquer. Mycoses 1994; 37: 97–100PubMedGoogle Scholar
  173. 173.
    Gupta AK. Amorolfine: an overview. Drugs Today 1995; 31: 145–53Google Scholar
  174. 174.
    Haria M, Bryson HM. Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995; 49: 103–20PubMedCrossRefGoogle Scholar
  175. 175.
    Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin Exp Dermatol 1992; 17: 61–70PubMedCrossRefGoogle Scholar
  176. 176.
    Polak AM. Preclinical data and mode of action of amorolfine. Clin Exp Dermatol 1992; 17 Suppl. 1: 8–12CrossRefGoogle Scholar
  177. 177.
    Roncari G, Ponelle Ch, Zumbrunnen R, et al. Percutaneous absorption of amorolfine following a single topical application of an amorolfine cream formulation. Clin Exp Dermatol 1992; 17: 33–6PubMedCrossRefGoogle Scholar
  178. 178.
    Nolting S, Reinel D, Semig G, et al. Amorolfine spray in the treatment of foot mycoses (a dose-finding study). Br J Dermatol 1993; 129: 170–4PubMedCrossRefGoogle Scholar
  179. 179.
    Franz TJ. Absorption of amorolfine through human nail. Dermatology 1992; 184: 18–20PubMedCrossRefGoogle Scholar
  180. 180.
    Polak A. Kinetics of amorolfine in human nails. Mycoses 1993; 36: 101–3PubMedCrossRefGoogle Scholar
  181. 181.
    Franz TJ. Percutaneous absorption: on the relevance of in-vitro data. J Invest Dermatol 1975; 64: 190–5PubMedCrossRefGoogle Scholar
  182. 182.
    Zaug M. Amorolfine nail lacquer: clincal experience in onychomycosis. J Eur Acad Dermatol Venereol 1995; 4 Suppl. 1: S23–30CrossRefGoogle Scholar
  183. 183.
    Rigopoulos D, Katsambas A, Antoniou C, et al. Discoloration of the nail plate due to the misuse of amorolfine 5% nail lacquer. Acta Derm Venereol (Stockh) 1996; 76: 83–4Google Scholar
  184. 184.
    Nussbaumer P, Dorfstätter G, Grassberger MA, et al. Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment. J Med Chem 1993; 36: 2115–20PubMedCrossRefGoogle Scholar
  185. 185.
    Maeda T, Takase M, Ishibashi A, et al. Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent. Yakugaku Zasshi 1991; 111: 126–37PubMedGoogle Scholar
  186. 186.
    Fukushiro R, Urabe H, Kagawa S, et al. Butenafine hydrochloride, a new antifungal agent: clinical and experimental study. In: Yamaguchi H, Kobayashi GS, Takahashi H, editors. Recent progress in antifungal therapy. New York: Marcel Dekker, 1992: 147–57Google Scholar
  187. 187.
    Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol 1997; 36: S3–8PubMedCrossRefGoogle Scholar
  188. 188.
    Tschen E, Elewski B, Gorsulowsky DC, Pariser DM. Treatment of interdigital tinea pedis with a 4-week once daily regimen of butenafine hydrochloride 1% cream. J Am Acad Dermatol 1997; 36: S9–14PubMedCrossRefGoogle Scholar
  189. 189.
    Savin R, De Villez RL, Elewski B, et al. One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial. J Am Acad Dermatol 1997; 36: S15–9PubMedCrossRefGoogle Scholar
  190. 190.
    Lesher JL, Babel DE, Stewart DM, et al. Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehicle-controlled, double-blind trial. J Am Acad Dermatol 1997; 36: S20–4PubMedCrossRefGoogle Scholar
  191. 191.
    Greer DL, Weiss J, Rodriguez DA, et al. A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent. J Am Acad Dermatol 1997; 37: 231–5PubMedCrossRefGoogle Scholar
  192. 192.
    Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988; 1: 187–217PubMedGoogle Scholar
  193. 193.
    Lackner TE, Clissold SP. Bifonazole: a review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1989; 38: 204–25PubMedCrossRefGoogle Scholar
  194. 194.
    Plempel M, Regel E, Büchel KH. Antimycotic efficacy of bifonazole in vitro and in vivo. Drug Res 1983; 33: 517–24Google Scholar
  195. 195.
    Patzschke K, Ritter W, Siefert HM, et al. Pharmacokinetic studies following systemic and topical administration of radiolabeled bifonazole in man. Arzneimittel Forschung 1983; 33: 745–50PubMedGoogle Scholar
  196. 196.
    Stettendorf S. Bifonazole — a synopsis of clinical trials worldwide. Dermatologica 1984; 169: 69–76PubMedCrossRefGoogle Scholar
  197. 197.
    Wheatley D, Richardson MD, Scott EM. Tinea infections treated with bifonazole gel. Mycoses 1988; 31: 471–5PubMedCrossRefGoogle Scholar
  198. 198.
    Galimberti RL, Belli L, Negroni R, et al. Treatment of tinea pedis interdigitalis with bifonazle, 1% gel. Dermatologica 1984; 169: 107–10PubMedCrossRefGoogle Scholar
  199. 199.
    Smith EB, Tschen E. Treatment of interdigital tinea pedis and tinea versicolor with bifonazole 1% solution applied once daily. In: Fromtling RA, editor. Recent trends in discovery, development and evaluation of antifungal agents. Barcelona: JR Prous Science Publishers, 1987: 407–14Google Scholar
  200. 200.
    Goffe BS. Response of tinea corporis/cruris and tinea versicolor to once-a-day topical treatment with bifonazole cream — a safety and efficacy study. In: Fromtling RA, editor. Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona: JR Prous Science Publishers, 1987: 423–9Google Scholar
  201. 201.
    Mora RG, Greer DL, Jolly HW. Prospective analysis of the response of tinea versicolor to topical application of Bifonazole 1 % cream. In: Fromtling RA, editor. Recent trends in the discovery, development, and evaluation of antifungal agents. Barcelona: JR Prous Science Publishers, 1987: 415–21Google Scholar
  202. 202.
    Soyinka F. Bifonazole in the treatment of fungal skin infections in the tropics: a clinical and mycological study. Cur Med Res Opin 1987; 10: 390–6CrossRefGoogle Scholar
  203. 203.
    Del Palacio Hernanz A, López Gómez S, Iglesias Diez L. Short course bifonazole therapy in pityriasis versicolor. Clin Exp Dermatol 1987; 12: 270–1PubMedCrossRefGoogle Scholar
  204. 204.
    Chu AC. Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor. Dermatologica 1984; 169 Suppl. 1: 81–6CrossRefGoogle Scholar
  205. 205.
    Mora RG, Greer DL. Comparative efficacy and tolerance of 1% bifonazole cream and bifonazole cream vehicle in patients with tinea versicolor. Dermatologica 1984; 169: 87–92PubMedCrossRefGoogle Scholar
  206. 206.
    Aste N, Pau M, Cordaro CI, et al. Double-blind study with fenticonazole or bifonazole lotions in pityriasis versicolor. Int J Clin Pharm Res 1988; 8: 271–3Google Scholar
  207. 207.
    Hay RJ, Adriaans B, Midgley G, et al. A single application of bifonazole 1% lotion in pityriasis versicolor. Clin Exp Dermatol 1987; 12: 315PubMedCrossRefGoogle Scholar
  208. 208.
    Galimberti R, Belli L, Gatti JC, et al. An open, multicentre assessment of the effectiveness of bifonazole in the treatment of tinea (pityriasis) versicolor. Pharmatherapeutica 1985; 4: 109–12PubMedGoogle Scholar
  209. 209.
    Galimberti RL, Bonino M, Flores V, et al. Ultra-short topical treatment of pityriasis versicolor with 2.5% bifonazole cream. Clin Exp Dermatol 1993; 18: 25–9PubMedCrossRefGoogle Scholar
  210. 210.
    Hernàndez-Pèrez E. A comparison between two different regimens of monthly application with bifonazole spray 1% in pityriasis versicolor. Int J Dermatol 1990; 29: 438–40PubMedCrossRefGoogle Scholar
  211. 211.
    Segal R, David M, Ingber A, et al. Treatment with bifonazole shampoo for seborrhea and seborrheic dermatitis: a randomized, double-blind study. Acta Derm Venereol (Stockh) 1992; 72: 454–5Google Scholar
  212. 212.
    Walker KAM, Braemer AC, Hitt S, et al. l-[4-(4-chlorophenyl)-2-(2,6 dichlorophenylthio)-n-butyl]-lH-imidazole nitrate, a new potent antifungal agent. J Med Chem 1978; 21: 840–3PubMedCrossRefGoogle Scholar
  213. 213.
    Droegemueller W, Adamson GD, Brown D, et al. Three day treatment with butoconazole nitrate for vulvovaginal candidiasis. Obstet Gynecol 1984; 64: 530–4PubMedGoogle Scholar
  214. 214.
    Tatum DM, Eggleston M. Butoconazole nitrate. Infect Control Hosp Epidemiol 1988; 9(3): 122–4PubMedCrossRefGoogle Scholar
  215. 215.
    Hajman AJ. Vulvovaginal candidosis: comparison of 3-day treatment with 2% butoconazole nitrate cream and 6-day treatment with 1% clotrimazole cream. J Int Med Res 1988; 16: 367–75PubMedGoogle Scholar
  216. 216.
    Bradbeer CS, Mayhew SR, Barlow D. Butoconazole and miconazole in treating vaginal candidiasis. Genitourin Med 1985; 61: 270–2PubMedGoogle Scholar
  217. 217.
    Plempel M, Bartmann K, Biichel H, et al. Bay B5097, a new orally applicable antifungal substance with broad spectrum activity. Antimicrob Agents Chemother 1969; 9: 271–4PubMedGoogle Scholar
  218. 218.
    Holt RJ, Newman RL. Laboratory assessment of the antimycotic drug clotrimazole. J Clin Pathol 1972; 25: 1089–97PubMedCrossRefGoogle Scholar
  219. 219.
    Plempel M, Bartmann K, Biichel KH, et al. Antimycotic properties of clotrimazole. Postgrad Med J 1974 Jul; 50 Suppl. 1: 11–2Google Scholar
  220. 220.
    Oberste-Lehn H. Ideal properties of a modern antifungal agent — the therapy of mycoses with clotrimazole. Postgrad Med J 1974 Jul: 50 Suppl. 1: 51–3PubMedGoogle Scholar
  221. 221.
    Polemann G. Clinical experience in the local treatment of dermatomycoses with clotrimazole. Postgrad Med J 1974 Jul; 50 Suppl. 1: 54–6Google Scholar
  222. 222.
    Clayton YM, Connor BL. Clinical trial of clotrimazole in the treatment of superficial fungal infections. Postgrad Med J 1974 Jul; 50 Suppl. 1: 66–8PubMedGoogle Scholar
  223. 223.
    Zaias N, Battistini F. Superficial mycoses. Arch Dermatol 1977; 113: 307–8PubMedCrossRefGoogle Scholar
  224. 224.
    Ipp MM, Boxall L, Gelfand EW. Clotrimazole: intermittent therapy in chronic mucocutaneous candidiasis. Am J Dis Child 1977; 131: 305–7PubMedGoogle Scholar
  225. 225.
    Male O. A double-blind comparison of clotrimazole and tolnaftate therapy of superficial dermatophytoses. Postgrad Med J 1974 Jul; 50 Suppl. 1: 75–6PubMedGoogle Scholar
  226. 226.
    Naftifine Podiatric Study Group. Naftifine cream 1% versus clotrimazole cream 1% in the treatment of tinea pedis. J Am Podiatr Med Assoc 1990; 80: 314–8Google Scholar
  227. 227.
    Fredriksson T. Topical treatment of superficial mycoses with clotrimazole. Postgrad Med J 1974 Jul; 50 Suppl. 1: 62–4Google Scholar
  228. 228.
    Gip L. The topical therapy of pityriasis versicolor with clotrimazole. Postgrad Med J 1974 Jul; 50 Suppl. 1: 59–60Google Scholar
  229. 229.
    Clayton R, Du Vivier A, Savage M. Double-blind trial of 1% clotrimazole cream and whitfield ointment in the treatment of pityriasis versicolor. Arch Dermatol 1977; 113: 849–50PubMedCrossRefGoogle Scholar
  230. 230.
    Clayton YM, Connor BL. Comparison of clotrimazole cream, Whitfield’s ointment and nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis. Br J Dermatol 1973; 89: 297–303PubMedCrossRefGoogle Scholar
  231. 231.
    Shadomy S. In. vivo studies with bayb 5097. Antimicrob Agents Chemother 1970: 169–74Google Scholar
  232. 232.
    Ogata M, Matsumoto H, Hamada Y, et al. l-[l-[2-[(3- Chlorobenzyl)oxy]phenyl]vinyl]-lH-imidazole hydrochloride, a new potent antifungal agent. J Med Chem 1983; 26: 768PubMedCrossRefGoogle Scholar
  233. 233.
    Meinicke K, Michel G. Croconazole: a new broad spectrum agent in the treatment of fungal skin infections. Int J Clin Pharm Res 1994; 14: 139–48Google Scholar
  234. 234.
    Michel G. Croconazole. Drugs Today 1993; 29: 307Google Scholar
  235. 235.
    Kuhlwein A, Busch T. Tinea inguinalis und Tinea pedis: Croconazol versus Bifonazol in der Lokaltherapie. Therapiewoche 1990; 40: 1643Google Scholar
  236. 236.
    Beierdörffer H, Michel G, Kehr K. Croconazole in the treatment of tinea pedis. Mycoses 1995; 38: 501–7PubMedCrossRefGoogle Scholar
  237. 237.
    Shono M, Hayashi K, Sugimoto R. Allergic contact dermatitis from croconazole hydrochloride. Contact Derm 1989; 21: 225–7PubMedCrossRefGoogle Scholar
  238. 238.
    Font E, Freixes J, Julve J. Perfil del nuevo antimicotico topico eberconazol. Rev Iberoam Micol 1994; 11: 58–9Google Scholar
  239. 239.
    Tomas JM, Camprubi S, Merino S, et al. Inhibition of two imidazole antimycotics, eberconazole and clotrimazole, by different components of Candida albicans serotype B membrane protoplasts. Int J Antimicrob Agents 1993; 3: 61–4PubMedCrossRefGoogle Scholar
  240. 240.
    del Palacio A, Cuetara S, Rodriguez Noriega A. Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose-finding pilot study. Mycoses 1995; 38: 317–24PubMedCrossRefGoogle Scholar
  241. 241.
    Godefroi EF, Heeres J, Van Cutsem J, et al. The preparation and antimycotic properties of derivatives of 1-phenethyl-imidazole. J Med Chem 1969; 12: 784–91PubMedCrossRefGoogle Scholar
  242. 242.
    Heel RC, Brogden RN, Speight TM, et al. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs 1978; 16: 177–201PubMedCrossRefGoogle Scholar
  243. 243.
    Schaefar H, Stüttgen G. Absolute concentrations of an antimycotic agent, econazole, in the human skin after local application. Drugs 1976; 26: 432–5Google Scholar
  244. 244.
    Fredriksson T. Treatment of dermatomycoses with topical econazole and clotrimazole. Curr Ther Res 1979; 25: 590–4Google Scholar
  245. 245.
    Kates SG, Myung KB, McGinley KJ, et al. The antibacterial efficacy of econazole nitrate in interdigital toe web infections. J Am Acad Dermatol 1990; 22: 583–6PubMedCrossRefGoogle Scholar
  246. 246.
    Cullen SI, Millikan LE, Mullen RH. Treatment of tinea pedis with econazole nitrate cream. Cutis 1986; 7: 388–9Google Scholar
  247. 247.
    Daily AD, Kramer KJ, Rex IH, et al. Econazole nitrate (Spectazole) cream, 1 percent: a topical agent for the treatment of tinea pedis. Cutis 1985; 35: 278–9PubMedGoogle Scholar
  248. 248.
    Grigoriu D, Pallarés JL. Follow-up study after more than one year including 100 patients treated for superficial mycoses. Dermatologica 1980; 160: 62–8PubMedCrossRefGoogle Scholar
  249. 249.
    Cullen SI, Rex HI, Thorne EG. A comparison of a new antifungal agent, 1% econazole nitrate (Spectazole®) cream versus 1% clotrimazole cream in the treatment of intertriginous candidosis. Curr Ther Res 1984; 35: 606–9Google Scholar
  250. 250.
    Wong ESM, Hay RJ, Clayton YM, et al. Comparison of the therapeutic effect of ketoconazole tablets and econazole lotion in the treatment of chronic paronychia. Clin Exp Dermatol 1984; 9: 489–96PubMedCrossRefGoogle Scholar
  251. 251.
    Hira SK, Din SN, Patel JS. Econazole 1% in the treatment of pityriasis versicolor in Zambia. J Am Acad Dermatol 1985; 12: 580–1PubMedCrossRefGoogle Scholar
  252. 252.
    Vicik GJ, Mendiones M, Qinones CA, et al. A new treatment for tinea versicolor using econazole nitrate 1.0 percent cream once a day. Cutis 1984; 33: 570–1PubMedGoogle Scholar
  253. 253.
    Brenner M. Efficacy of twice-daily dosing of econazole nitrate 1% cream for tinea pedis. J Am Podiatr Med Assoc 1990; 80: 583–7PubMedGoogle Scholar
  254. 254.
    Mackie RM. Topical econazole in cutaneous fungal infections. Practitioner 1980; 224: 1311–3PubMedGoogle Scholar
  255. 255.
    Nardi D, Cappelletti R, Catto A, et al. New alpha-aryl-beta,N-imidazolylethyl benzyl and naphthylmethyl ethers with antimycotic and antibacterial activity. Arzneimittel Forschung 1981; 31: 2123PubMedGoogle Scholar
  256. 256.
    Tajana R, Cappelletti R, Leonardi A, et al. Synthesis and antimycotic activity of alpha-aryl-beta, N-imidazoly-alkyl benzyl ethers. Arzneimittel Forschung 1981; 31: 2121PubMedGoogle Scholar
  257. 257.
    Costa AL. In. vitro antimycotic activity of fenticonazole (REC 15-1476). Mykosen 1982; 25: 47PubMedCrossRefGoogle Scholar
  258. 258.
    Veronese M, Barzaghi D, Bertoncini A. Antifungal activity of fenticonazole in experimental dermatomycosis and candidiasis. Arzneimittel Forschung 1981; 31: 2137PubMedGoogle Scholar
  259. 259.
    Veronese M, Barzaghi D, Bertoncini A, et al. Fenticonazole: a new antifungal imidazole derivative. In. vitro and in. vivo antimycotic activity. Mykosen 1984; 27: 192Google Scholar
  260. 260.
    Veronese M, Salvaterre M, Barzaghi D. Fenticonazole, a new imidazole derivative with antibacterial and antifungal activity: in vitro study. Arzneimittel Forschung 1981; 31: 2133PubMedGoogle Scholar
  261. 261.
    Clerico R, Ribuffo A. Efficacy and tolerance of fenticonazole versus miconazole cream. Int J Clin Pharm Res 1987; 7: 77–81Google Scholar
  262. 262.
    Veronese M, Bertoncini A, Monici Preti P. Evaluation of the skin retention time of imidazole derivatives. Mykosen 1987; 30: 386–90PubMedCrossRefGoogle Scholar
  263. 263.
    Jung EG, Bisco A, Azzollini E, et al. Fenticonazole cream once daily in dermatomycosis, a double-blind controlled trial versus bifonazole. Dermatologica 1988; 177: 104–8PubMedCrossRefGoogle Scholar
  264. 264.
    Leiste D, Braun W, Fegeier W, et al. A double-blind clinical trial of fenticonazole (2%) spray versus naftifine (1%) spray in patients with cutaneous mycoses. Curr Med Res Opin 1989; 11: 567–75PubMedCrossRefGoogle Scholar
  265. 265.
    Aste N, Pau M, Zucca M, et al. Clinical experience with fenticonazole 2% formulation in the treatment of dermato-mycoses and pityriasis versicolor. Int J Clin Pharm Res 1987; 7: 503–6Google Scholar
  266. 266.
    Athow-Frost TAM, Freeman K, Mann TAN, et al. Clinical evaluation of fenticonazole cream in cutaneous fungal infections: a comparison with miconazole. Curr Med Res Opin 1986; 10: 107–16PubMedCrossRefGoogle Scholar
  267. 267.
    Kokoschka EM, Niebauer G, Molinari M, et al. Treatment of dermatomycoses with topical fenticonazole and econazole. Mykosen 1986; 29: 45–50PubMedCrossRefGoogle Scholar
  268. 268.
    Sartani A, Cordaro CI, Panconesi E. A multicenter trial with a new imidazole derivative, fenticonazole, in superficial fungal skin infections. Curr Ther Res 1988; 43: 1194–203Google Scholar
  269. 269.
    Bartolí J, Algueró M, Boncompte E, et al. Synthesis and antifungal activity of a series of difluorotrityl-imidazoles. Arzneimittel Forschung 1992; 42: 832–5Google Scholar
  270. 270.
    Garcia Rafanell J, Dronda MA, Merlos M, et al. In vitro and in vivo studies with flutrimazole, a new imidazole derivative with antifungal activity. Arzneimittel Forschung 1992; 42: 836–40PubMedGoogle Scholar
  271. 271.
    Izquierdo I, Bayes M, Jané J, et al. Local and systemic tolerance of flutrimazole skin creams following single and repeated topical application in healthy volunteers. Arzneimittel Forschung 1992; 42: 859–60PubMedGoogle Scholar
  272. 272.
    Duchène P, Papalexiou P, Ramis J, et al. Pharmacokinetic profile of [14C]flutrimazole following single topical application in normal and scarified skin of healthy volunteers. Arzneimittel Forschung 1992; 42: 861–3PubMedGoogle Scholar
  273. 273.
    Alomar A, Videla S, Delgadillo J, et al. Flutrimazole 1% dermal cream in the treatment of dermatomycoses: a multicentre, double-blind, randomized, comparative clinical trial with bifonazole 1% cream. Dermatology 1995; 190: 295–300PubMedCrossRefGoogle Scholar
  274. 274.
    Del Palacio A, Cuétara S, Izquierdo I, et al. A double-blind, randomized comparative trial: flutrimazole 1% solution versus bifonazole 1% solution once daily in dermatomycoses. Mycoses 1995; 38: 395–403PubMedCrossRefGoogle Scholar
  275. 275.
    Binet O, Soto-Melo J, Delgadillo J, et al. Flutrimazole 1% dermal cream in the treatment of dermatomycoses: a randomized, multicentre, double-blind, comparative clinical trial with 1% clotrimazole cream. Mycoses 1994; 37: 455–9PubMedCrossRefGoogle Scholar
  276. 276.
    Kessler H-J. Mikrobiologische Untersuchungen mit Isoconazolnitrat, einem breitspektrum-Antimykoticum aus der Gruppe der Imidazol-derivative. Arzneimittel Forschung 1979; 29: 1344–51PubMedGoogle Scholar
  277. 277.
    Dykes PJ, Marks R, Tauber U. The retention of isoconazole in the skin after once or twice daily application of 1% isoconazole nitrate cream (Travogen) over a 14-day period. Clin Exp Dermatol 1986; 11: 365–70PubMedCrossRefGoogle Scholar
  278. 278.
    Gugnani HC, Akpata LE, Gugnani MK, et al. Isoconazole nitrate in the treatment of tropical dermatomycoses. Mycoses 1994; 37: 39–41PubMedCrossRefGoogle Scholar
  279. 279.
    Täuber U, Rach P, Lachnit U. Persistence of isoconazole in vaginal secretion after single application. Mykosen 1984; 27: 97–101PubMedCrossRefGoogle Scholar
  280. 280.
    Walther M. Feldstudie die Einmaltherapie von Vaginal-mykosen mit Isoconazolnitrat. Praxis 1982; 71: 152–6PubMedGoogle Scholar
  281. 281.
    Heeres J, Backx LJJ, Mostmans JH, et al. Antimycotic imidazoles: 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem 1983; 22: 1003–5Google Scholar
  282. 282.
    Thienpont D, Van Cutsem J, Van Gervan F, et al. Ketoconazole — a new broad spectrum orally active antimycotic. Experientia 1979; 35: 606–7PubMedCrossRefGoogle Scholar
  283. 283.
    Odds FC, Milne LJR, Gentles JC, et al. The activity in. vitroand invivo of a new imidazole antifungal ketoconazole. J Antimicrob Chemother 1980; 6: 97–104PubMedCrossRefGoogle Scholar
  284. 284.
    Ketoconazole 2% cream product information [editorial]. In: Physicians’ desk reference. 51st ed. Montvale (NJ): Medical Economics Company Inc., 1997: 1344–5Google Scholar
  285. 285.
    Odds FC, Webster CE, Abbott AB. Antifungal relative inhibition factors: BAY 1-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared invitrowith nine established antifungal agents. J Antimicrob Chemother 1984; 14: 105–14PubMedCrossRefGoogle Scholar
  286. 286.
    Lester M. Ketoconazole 2 percent cream in the treatment of tinea pedis, tinea cruris, and tinea corporis. Cutis 1995; 55: 181–3PubMedGoogle Scholar
  287. 287.
    Greer D, Jolly HW Topical ketoconazole treatment of cutaneous candidiasis. J Am Acad Dermatol 1988; 18: 748–9PubMedCrossRefGoogle Scholar
  288. 288.
    Ford GP, Farr PM, Ive FA, et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111: 603–7PubMedCrossRefGoogle Scholar
  289. 289.
    Leyden JJ, McGinley KJ, Kligman AM. Role of microorganisms in dandruff. Arch Dermatol 1976; 112: 333PubMedCrossRefGoogle Scholar
  290. 290.
    Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984; 3: 235–42CrossRefGoogle Scholar
  291. 291.
    Skinner RB, Noah PW, Taylor RM, et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985; 12: 852–6PubMedCrossRefGoogle Scholar
  292. 292.
    Stratigos JD, Antoniou C, Katsambas A, et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis: a double-blind comparative study. J Am Acad Dermatol 1988; 19: 850–3PubMedCrossRefGoogle Scholar
  293. 293.
    Katsambas A, Antoniou CH, Frangouli E, et al. A double-blind trial of treatment of seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream. Br J Dermatol 1989; 121: 353–7PubMedCrossRefGoogle Scholar
  294. 294.
    Carr MM, Pryce DM, Ive FA. Treatment of seborrhoeic dermatitis with ketoconazole: I. Response of seborrhoeic dermatitis of the scalp to topical ketoconazole. Br J Dermatol 1987; 116: 213–6Google Scholar
  295. 295.
    Green CA, Farr PM, Shuster S. Treatment of seborrheic dermatitis with ketoconazole: II. Response of seborrheic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol 1987; 116: 217–21Google Scholar
  296. 296.
    Ive FA. An overview of experience with ketoconazole shampoo. Br J Clin Pract 1991; 45: 279–84PubMedGoogle Scholar
  297. 297.
    McGrath J, Murphy GM. The control of seborrhoeic dermatitis and dandruff by antipityrosoral drugs. Drugs 1991; 41: 178–84PubMedCrossRefGoogle Scholar
  298. 298.
    Cauwenbergh G, De Doncker P, Schrooten P, et al. Treatment of dandruff with a 2% ketoconazole scalp gel: a double-blind placebo-controlled study. Int J Dermatol 1986; 25(8): 541PubMedCrossRefGoogle Scholar
  299. 299.
    Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol 1995; 132: 441–5PubMedCrossRefGoogle Scholar
  300. 300.
    Brown M, Evans TW, Poyner T, et al. The role of ketoconazole 2% shampoo in the treatment and prophylactic management of dandruff. J Dermatol Treat 1990; 1: 177–9CrossRefGoogle Scholar
  301. 301.
    Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with topical ketoconazole. Lancet 1984; II: 1271–2CrossRefGoogle Scholar
  302. 302.
    Taieb A, Legrain V, Palmier C, et al. Topical ketoconazole for infantile seborrhoeic dermatitis. Dermatologica 1990; 181: 26–32PubMedCrossRefGoogle Scholar
  303. 303.
    Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol 1986; 15: 500–3PubMedCrossRefGoogle Scholar
  304. 304.
    Meisel C. Treatment of tinea versicolor with 2% ketoconazole emulsion vs. climbazole and placebo: a double blind study. Z Hautkr 1991; 66: 415–8Google Scholar
  305. 305.
    Rekacewicz I, Guillaume JC, Benkhraba F, et al. Étude en double insu contre excipient du kétoconazole lotion moussante à 2 p. 100 en application unique dans le traitement du Pityriasis versicolor. Ann Dermatol Venereol 1990; 117: 709–11Google Scholar
  306. 306.
    Ketoconazole product monograph. Mississauga (Ont): Janssen Pharmaceutica Inc., 1995 MayGoogle Scholar
  307. 307.
    Niwano Y, Tabuchi T, Kanai K, et al. Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent. Antimicrob Agents Chemother 1995; 39: 2353–5PubMedCrossRefGoogle Scholar
  308. 308.
    Niwano Y, Seo A, Kanai K, et al. Therapeutic efficacy of lanoconazole, a new imidazole antimycotic agent, for experimental cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother 1994; 38: 2204–6PubMedCrossRefGoogle Scholar
  309. 309.
    Ohmi T, Konaka S, Uchida M, et al. Antifungal activity of the new agent lanoconazole in two tinea models. Arzneimittel Forschung 1991; 41: 847–51PubMedGoogle Scholar
  310. 310.
    Oka H, Niwano Y, Ohmi T, et al. Therapeutic efficacy of lanoconazole in formulations of clinical use on experimental dermatophytosis in guinea pigs. Arzneimittel Forschung 1992; 42(I): 345–9PubMedGoogle Scholar
  311. 311.
    Takahashi H. New topical imidazoles under development in Japan: TJN-318 (NND-318). Evaluation of antifungal activities and the result of clinical open study on dermatomycoses. In: Yamaguchi H, Kobayashi GS, Takahashi H, et al., editors. Recent progress in antifungal chemotherapy. New York: Marcel Dekker, Inc., 1991: 103–12Google Scholar
  312. 312.
    Godefroi EF, Heeres J, Van Custem J, et al. The preparation and antimycotic properties of derivatives of 1-phenethylimidazole. J Med Chem 1969; 12: 784–91PubMedCrossRefGoogle Scholar
  313. 313.
    Van Cutsem JM, Thienpont D. Miconazole: a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy 1972; 17: 392–404PubMedCrossRefGoogle Scholar
  314. 314.
    Odds FC, Abbott Ab, Pye G, et al. Improved method for estimation of azole antifungal inhibitory concentrations against Candidaspecies, based on azole/antibiotic interactions. J Med Vet Mycol 1986; 24: 305–11PubMedCrossRefGoogle Scholar
  315. 315.
    Yamaguchi T, Hiratani T, Plempel M. Invitrostudies of a new imidazole antimycotic, bifonazole, in comparison with clotrimazole and miconazole. Arzneimittel Forschung 1983; 33: 546–51PubMedGoogle Scholar
  316. 316.
    Heel RC, Brogden RN, Pakes GE, et al. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 1980; 19: 7–30PubMedCrossRefGoogle Scholar
  317. 317.
    Mandy SJ, Garrott MTC. Miconazole treatment for severe dermatophytoses. JAMA 1974; 230(1): 72–5PubMedCrossRefGoogle Scholar
  318. 318.
    Fulton JE. Miconazole therapy for endemic fungal disease. Arch Dermatol 1975; 113: 596–8CrossRefGoogle Scholar
  319. 319.
    Ongley RC. Efficacy of topical miconazole treatment of tinea pedis. Can Med Assoc J 1978; 119: 353–4PubMedGoogle Scholar
  320. 320.
    Nolting S, Strauss WB. Treatment of impetigo and ecthyma: a comparison of sulconazole with miconazole. Int J Dermatol 1988; 27: 716–9PubMedCrossRefGoogle Scholar
  321. 321.
    Tanenbaum L, Anderson C, Rosenberg MJ, et al. 1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor. Arch Dermatol 1984; 120: 216–9PubMedCrossRefGoogle Scholar
  322. 322.
    Pitcher DG, Noble WC, Seville RH. Treatment of erythrasma with miconazole. Clin Exp Dermatol 1979; 4: 453–6PubMedCrossRefGoogle Scholar
  323. 323.
    Mesquita-Guimaraes J, Ramos S, Tavares MR, et al. A double-blind clinical trial with a lotion containing 5% benzoyl peroxide and 2% miconazole in patients with acne vulgaris. Clin Exp Dermatol 1989; 14: 357–60PubMedCrossRefGoogle Scholar
  324. 324.
    Ogawa M, Matsuda H, Eto H, et al. Synthesis and antifungal activities of a series of (1,2-distributed vinyl) imidazoles. Chem Pharm Bull 1991; 39: 2301–7PubMedCrossRefGoogle Scholar
  325. 325.
    Tsuboi R, Matsumoto T, Ogawa H, et al. Hyperkeratotic chronic tinea pedis treated with neticonazole cream. Int J Dermatol 1996; 35: 371–3PubMedCrossRefGoogle Scholar
  326. 326.
    Asaoka T, Kawahara R, Iwasa A, et al. Antifungal activity of S5717, a new imidazole antimycotic: 1.Invitroantimicrobial activity. Chemotherapy 1990; 38: 753–68Google Scholar
  327. 327.
    Thile KL, Zirngibl MH, Pfeinninger M, et al. Antimykotisch wirksame Imidazolylalkene: syntheses und Rontogenstrukturanalyse von Omoconazol. Helv Chim Acta 1987; 70: 441CrossRefGoogle Scholar
  328. 328.
    Zirngibl L, Fischer J, Jahn U, et al. Structure-activity relationships of 2-(1H-imidazol-1-yl) vinyl ethers. Ann NY Acad Sci 1988; 544: 63–73PubMedCrossRefGoogle Scholar
  329. 329.
    Gip L. The invitrodetermination of lingering antimycotic effect of two 1% omoconazole-nitrate cream formulations following single topical application. Mycoses 1988: 31: 155–8PubMedCrossRefGoogle Scholar
  330. 330.
    Nishiyama Y, Itoyama T, Yamaguchi H. Ultrastructural alterations of Candidaalbicansinduced by a new imidazole antimycotic omoconazole nitrate. Microbiol Immunol 1997; 41: 395–402PubMedGoogle Scholar
  331. 331.
    Mixich G, Thiele K. Ein Beitrag zur stereospezifischen Synthese von antimykotisch wirksamen Imidazolyloximäthern. Oxiconazol-nitrat (Sgd 301-76), ein neues Breitbandanti-mykotikum. Arzneimittel Forschung 1979; 29: 1510–3Google Scholar
  332. 332.
    Jegasothy BV, Pakes GE. Oxiconazole nitrate: pharmacology, efficacy, and safety of a new imidazole antifungal agent. Clin Ther 1991; 13: 126–41PubMedGoogle Scholar
  333. 333.
    Gebhart RJ, Espinel-Ingroff A, Shadomy S. In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy 1984; 30: 244–7PubMedCrossRefGoogle Scholar
  334. 334.
    Polak A. Oxiconazole, a new imidazole derivative. Arzneimittel Forschung 1982; 32: 17–24PubMedGoogle Scholar
  335. 335.
    Ramelet AA, Walker-Nasir E. One daily application of oxiconazole cream is sufficient for treating dermatomycoses. Dermatologica 1987; 175: 293–5PubMedCrossRefGoogle Scholar
  336. 336.
    Polak A. Antifungal activity of four antifungal drugs in the cutaneous retention time test. Sabouraudia 1984; 22: 501–3PubMedCrossRefGoogle Scholar
  337. 337.
    Ellis CN, Gammon WR, Goldfarb MT, et al. A placebo-controlled evaluation of once-daily versus twice-daily oxiconazole nitrate (1%) cream in the treatment of tinea pedis. Curr Ther Res 1989; 46: 269–76Google Scholar
  338. 338.
    Pariser DM, Pariser RJ. Oxiconazole nitrate lotion, 1 percent: an effective treatment for tinea pedis. Cutis 1994; 54: 43–4PubMedGoogle Scholar
  339. 339.
    Gip L. Comparison of oxiconazole (Ro 13-8996) and econazole in dermatophytoses. Mykosen 1984; 27: 295–302PubMedCrossRefGoogle Scholar
  340. 340.
    Wagner W. Comparison of clinical efficacy and tolerability of oxiconazole one dose vs. two doses daily. Mykosen 1986; 29: 280–4Google Scholar
  341. 341.
    Gouveia DC, da Silva CJ. Oxiconazole in the treatment of vaginal candidiasis: single dose versus 3-day treatment with econazole. Pharmatherapeutica 1984; 3: 682–5PubMedGoogle Scholar
  342. 342.
    Gugnani HC, Ideyi C, Gugnani MK. Oxiconazole in the treatment of tropical dermatomycoses. Curr Ther Res 1993; 54(1): 122–5CrossRefGoogle Scholar
  343. 343.
    Raga M, Palacín C, Castelló JM, et al. Eur J Med Chem 1986; 21: 329Google Scholar
  344. 344.
    Farré M, Ugena B, Badenas JM, et al. Pharmacokinetics and tolerance of sertaconazole in man after repeated percutaneous administration. Arzneimittel Forschung 1992; 42: 752–4PubMedGoogle Scholar
  345. 345.
    Umbert P, Nasarre J, Bello A, et al. Phase II study of the therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of superficial mycoses caused by Candidaalbicans. Arzneimittel Forschung 1992; 42: 757–60PubMedGoogle Scholar
  346. 346.
    Nasarre J, Umbert P, Herrero E, et al. Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of pityriasis versicolor. Arzneimittel Forschung 1992; 42: 764–7PubMedGoogle Scholar
  347. 347.
    Van Esso D, Fajo G, Losada I, et al. Sertaconazole in the treatment of pediatric patients with cutaneous dermatophyte infections. Clin Ther 1995; 17: 264–9PubMedCrossRefGoogle Scholar
  348. 348.
    Yoshida H, Kasuga O, Yamaguchi T. Studies on antifungal activities of sulconazole:1. Invitroantimicrobial activity. Chemotherapy (Tokyo) 1984; 32: 477–84Google Scholar
  349. 349.
    Yoshida H, Kasuga O, Yamaguchi T, et al. Studies on antifungal activities of sulconazole: 2. Therapeutic effect of the cream formulation on experimental Trichophyton mentagrophytes infection of guinea pig. Chemotherapy (Tokyo) 1984; 32: 485–9Google Scholar
  350. 350.
    Lassus A, Forström S, Salo O. A double-blind comparison of sulconazole nitrate 1% cream with clotrimazole 1% cream in the treatment of dermatophytoses. Br J Dermatol 1989; 108: 195–8CrossRefGoogle Scholar
  351. 351.
    Akers WA, Lane A, Lynfield Y, et al. Sulconazole nitrate 1% cream in the treatment of chronic moccasin-type tinea pedis caused by Trichophytonrubrum. J Am Acad Dermatol 1989; 21: 686–9PubMedCrossRefGoogle Scholar
  352. 352.
    Tanenbaum L, Taplin D, Lavalle C, et al. Sulconazole nitrate cream 1% for treating tinea cruris and corporis. Cutis 1989; 44: 344–7PubMedGoogle Scholar
  353. 353.
    Gip L, Forström S. A double-blind parallel study of sulconazole nitrate 1% cream compared with miconazole 2% cream in dermatophytoses. Mykosen 1983; 26: 231–41PubMedCrossRefGoogle Scholar
  354. 354.
    Tanenbaum L, Anderson C, Rosenberg MJ, et al. Sulconazole nitrate 1.0 percent cream: a comparison with miconazole in the treatment of tinea pedis and tinea cruris/corporis. Cutis 1982; 30: 105–7PubMedGoogle Scholar
  355. 355.
    Lassus A, Forstrom S. A double-blind parallel study comparing sulconazole and econazole in the treatment of dermatophytoses. Mykosen 1984; 27: 592–8PubMedCrossRefGoogle Scholar
  356. 356.
    Tannenbaum L, Anderson C, Rosenberg MJ, et al. 1% sulconazole cream vs. 2% miconazole cream in the treatment of tinea versicolor. Arch Dermatol 1984; 120: 216–9Google Scholar
  357. 357.
    Tanenbaum L, Anderson C, Rosenberg M, et al. A new treatment for cutaneous candidiasis: sulconazole nitrate cream 1%. Int J Dermatol 1983; 22: 318–20PubMedCrossRefGoogle Scholar
  358. 358.
    Rajan VS, Thirumoorthy T. Treatment of cutaneous candidiasis: a double-blind, parallel comparison of sulconazole nitrate 1 % cream and clotrimazole 1% cream. Aust NZ J Med 1983; 24: 33–6Google Scholar
  359. 359.
    Heeres J, Hendrickx R, Van Cutsem J. Antimycotic imidazoles: 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal. J Med Chem 1983; 26: 611–3Google Scholar
  360. 360.
    Cauwenbergh G, Vanden Bossche H. Terconazole: pharmacology of a new antimycotic agent. J Reprod Med 1989; 34: 588–92PubMedGoogle Scholar
  361. 361.
    Van Custem J, Van Gerven F, Zaman R, et al. Terconazole — a new broad spectrum antifungal. Chemotherapy 1983; 29: 322–31CrossRefGoogle Scholar
  362. 362.
    Tolman EL, Isaacson DM, Rosenthale ME, et al. Anticandidal activities of terconazole, a broad-spectrum antimycotic. Anti-microb Agents Chemother 1986; 29: 986–91CrossRefGoogle Scholar
  363. 363.
    Vanden Bossche H, Marichal P. Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol 1991; 165: 1193–9Google Scholar
  364. 364.
    Thomason JL. Clinical evaluation of terconazole: United States Experience. J Reprod Med 1989; 34: 597–601PubMedGoogle Scholar
  365. 365.
    Hirsch HA. Clinical evaluation of terconazole: European experience. J Reprod Med 1989; 38: 593–5Google Scholar
  366. 366.
    Kjaeldgaard A. Comparison of terconazole and clotrimazole vaginal tablets in the treatment of vulvovaginal candidosis. Pharmatherapeutica 1986; 4: 525–31PubMedGoogle Scholar
  367. 367.
    Weisberg M. Terconazole: a new antifungal agent for vulvovaginal candidiasis. Clin Ther 1989; 11: 659–68PubMedGoogle Scholar
  368. 368.
    Moebius UM. Influenza-like syndrome after terconazole. Lancet 1988; II: 966–7CrossRefGoogle Scholar
  369. 369.
    Clissold SP, Heel RC. Tioconazole: a review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1986; 31: 29–51PubMedCrossRefGoogle Scholar
  370. 370.
    Vander Ploeg DE, De Villez RL. A new topical antifungal drug: tioconazole. Int J Dermatol 1984; 23: 681–3CrossRefGoogle Scholar
  371. 371.
    Marriott MS, Baird JRC, Brammer KW, et al. Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Dermatologica 1983; 166: 1–7PubMedCrossRefGoogle Scholar
  372. 372.
    O’Neill East M, Henderson JT, Jevons S. Tioconazole in the treatment of fungal infections of the skin. Dermatologica 1983; 166: 20–33PubMedCrossRefGoogle Scholar
  373. 373.
    Fredriksson T. Treatment of dermatomycoses with topical tioconazole and miconazole. Dermatologica 1983; 166: 14–9PubMedCrossRefGoogle Scholar
  374. 374.
    Kashin P, Phyfferoen MC, Gibbs DL. A comparative study of once versus twice daily treatment of dermatophyte and yeast infections with tioconazole (1% cream). J Int Med Res 1985; 13: 85–95Google Scholar
  375. 375.
    del Palacio Hernanz A, Gomez SL, Diez LI. A clinical and mycological assessment of tioconazole solution in the treatment of superficial dermatomycoses. Clin Ther 1987; 9: 333–8PubMedGoogle Scholar
  376. 376.
    Grigoriu D, Grigoriu A. Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma. Dermatologica 1983; 166: 8–13PubMedCrossRefGoogle Scholar
  377. 377.
    Clayton YM, Hay RJ, McGibbon DH, et al. Double blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma. Clin Exp Dermatol 1982; 7: 543–9PubMedCrossRefGoogle Scholar
  378. 378.
    Alchorne MMA, Paschoalick RC, Forjaz MHH. Comparative study of tioconazole and clotrimazole in the treatment of tinea versicolor. Clin Ther 1987; 9: 360–7PubMedGoogle Scholar
  379. 379.
    Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution — an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111–5PubMedCrossRefGoogle Scholar
  380. 380.
    Hay RJ, Clayton YM, Moore MK. Acomparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 1987; 12: 175–7PubMedCrossRefGoogle Scholar
  381. 381.
    Petranyi G, Georgopoulos A, Mieth H. In vivo antimycotic activity of naftifine. Antimicrob Agents Chemother 1981; 19: 390–2PubMedCrossRefGoogle Scholar
  382. 382.
    Georgopoulos A, Petranyi G, Mieth H, et al. Invitroactivity of naftifine, a new antifungal agent. Antimicrob Agents Chemother 1981; 19: 386–9PubMedCrossRefGoogle Scholar
  383. 383.
    Stütz A. Synthesis and structure-activity correlations within allylamine antimycotics. Ann NY Acad Sci 1988; 544: 46–62PubMedCrossRefGoogle Scholar
  384. 384.
    Meinicke K, Striegel C, Weidinger G. Treatment of dermatomycoses with naftifine: therapeutic efficacy after once-a-day and twice-a-day application. Mykosen 1984; 27: 608–14PubMedCrossRefGoogle Scholar
  385. 385.
    Poelmann G. Antimycotic efficacy of naftifine after once-daily application. Mykosen 1985; 28 Suppl. 1: 113–8Google Scholar
  386. 386.
    Effendy I, Friedrich HC. Double-blind, randomized, comparative trial of naftifine solution (once-a-day) and clotrimazole solution (twice-a-day) in the treatment of dermatomycoses. Mykosen 1985; 28 Suppl. 1: 126–34Google Scholar
  387. 387.
    Sowden JM, Allen BR. Naftifine — an antifungal drug with anti-inflammatory properties? J Dermatol Treat 1990; 1: 27–8CrossRefGoogle Scholar
  388. 388.
    Jones TC. Treatment of dermatomycoses with topically applied allylamines: naftifine and terbinafine. J Dermatol Treat 1990; 1 Suppl. 2: 29–32CrossRefGoogle Scholar
  389. 389.
    Solomon B A, Lee WL, Geen SC, et al. Modification of neutrophil functions by naftifine. Br J Dermatol 1993; 128: 393–8PubMedCrossRefGoogle Scholar
  390. 390.
    Bojanovsky A, Haas P. Antimycotic efficacy of naftifine: double-blind comparative study with bifonazole in tinea pedis. Fortschr Med 1985; 103: 677–9PubMedGoogle Scholar
  391. 391.
    Dobson RL, Bagatell FD, Hickman JG, et al. Naftifine 1% cream in the treatment of tinea cruris and tinea corporis. Drug Invest 1991; 3: 57–9CrossRefGoogle Scholar
  392. 392.
    Dobson RL, Binder R, Hickman JG, et al. Once-daily naftifine cream 1% (Naftin) in the treatment of tinea pedis. Clin Trials J 1989; 26: 418–23Google Scholar
  393. 393.
    Gip L, Brundin G. A double-blind, two group multicentre study, comparing naftifine 1% cream with placebo cream in the treatment of tinea cruris. Mykosen 1987; 30 Suppl. 1: 38–41Google Scholar
  394. 394.
    Haas PJ, Tronnier H, Weidinger G. Naftifine in tinea pedis: double-blind comparison with clotrimazole. Mykosen 1987; 30 Suppl. 1: 50–6Google Scholar
  395. 395.
    Jordan RE, Rapini RP, Rex IJ, et al. Once-daily naftifine cream 1% in the treatment of tinea cruris and tinea coporis. Int J Dermatol 1990; 29: 441–2CrossRefGoogle Scholar
  396. 396.
    Kagawa S. Comparative clinical trial of naftifine and clotrimazole in tinea pedis, tinea cruris and tinea corporis. Mykosen 1987; 30 Suppl. 1: 63–9Google Scholar
  397. 397.
    Klaschka F, Gartmann H, Weidinger G. The antifungal agent naftifine: placebo-controlled therapeutic comparison in tinea pedis. Z Hautkr 1984; 59: 1218–25PubMedGoogle Scholar
  398. 398.
    Meinicke K, Striegel C, Weidinger G. Treatment of dermatomycoses with naftifine: therapeutic efficacy on application once daily and twice daily. Mykosen 1987; 30 Suppl. 1: 98–103Google Scholar
  399. 399.
    Millikan LE, Galen WK, Gewirtzman GB, et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis.J Am Acad Dermatol 1988; 18: 52–6PubMedCrossRefGoogle Scholar
  400. 400.
    Naftifine Gel Study Group. Naftifine gel in the treatment of tinea pedis: two double-blind, multicenter studies. Cutis 1991; 48: 85–8Google Scholar
  401. 401.
    Naftifine Podiatric Study Group. Naftifine cream 1% versus clotrimazole cream 1% in the treatment of tinea pedis. J Am Podiatr Med Assoc 1990; 80: 314–8Google Scholar
  402. 402.
    Nolting S, Weidinger G. Naftifine in severe dermatomycoses: econazole-controlled therapeutic comparison. Mykosen 1987; 30 Suppl. 1: 70–7Google Scholar
  403. 403.
    Schachner LA, Bagatell FK, Whittington CV, et al. The safety and efficacy of naftifine cream 1% in the treatment of tinea pedis. Adv Ther 1990; 7: 148–52Google Scholar
  404. 404.
    Smith EB, Breneman DL, Griffith RF, et al. Double-blind comparison of naftifine cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis. J Am Acad Dermatol 1992; 26: 125–7PubMedCrossRefGoogle Scholar
  405. 405.
    Smith EB, Wiss K, Hanifin JM, et al. Comparison of once- and twice-daily naftifine cream regimens with twice-daily clotrimazole in the treatment of tinea pedis. J Am Acad Dermatol 1990; 22: 1116–7PubMedCrossRefGoogle Scholar
  406. 406.
    Tronnier H. Inflammatory dermatomycoses: comparative study of naftifine and a combination of a corticosteroid and an imidazole derivative. Mykosen 1987; 30 Suppl. 1: 78–87Google Scholar
  407. 407.
    Evans EGV, James IGV, Seaman RAJ, et al. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol 1993; 129: 437–42PubMedCrossRefGoogle Scholar
  408. 408.
    Nada M, Hanafi S, Al-Omari H, et al. Naftifine versus miconazole/hydrocortisone in inflammatory dermatophyte infections. Int J Dermatol 1994; 33: 570–2PubMedCrossRefGoogle Scholar
  409. 409.
    Meyerson MS, Scher RK, Hochman LG, et al. Open-label study of the safety and efficacy of naftifine hydrochloride 1 percent gel in patients with distal subungual onychomycosis of the fingers. Cutis 1993; 51: 205–7PubMedGoogle Scholar
  410. 410.
    Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview: part II. J Am Acad Dermatol 1994; 30: 911–33PubMedCrossRefGoogle Scholar
  411. 411.
    Gupta AK, Shear NH, Sauder DN. New antifungal agents. Cur Opinion Dermatol 1993; 2: 200–6Google Scholar
  412. 412.
    Shear N, Gupta AK. Terbinafine for the treatment of pedal onychomycosis: a foot closer to the promised land of cured nails? Arch Dermatol 1995; 131: 937–42PubMedCrossRefGoogle Scholar
  413. 413.
    Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 Suppl. 39: 2–7CrossRefGoogle Scholar
  414. 414.
    Hill S, Thomas R, Smith SG, et al. An investigation of the pharmacokinetics of topical terbinafine (Lamisil) 1% cream. Br J Dermatol 1992; 127: 396–400PubMedCrossRefGoogle Scholar
  415. 415.
    Topical terbinafine for tinea infections. Med Lett Drugs Ther 1993; 35: 76–8Google Scholar
  416. 416.
    Smith EB, Noppakun N, Newton RC. Clinical trial of topical terbinafine (a new allylamine antifungal): the treatment of tinea pedis. J Am Acad Dermatol 1990; 23: 790–3PubMedCrossRefGoogle Scholar
  417. 417.
    Savin RC. Treatment of chronic tinea pedis (athlete’s foot type) with topical terbinafine. J Am Acad Dermatol 1990; 23: 786–9PubMedCrossRefGoogle Scholar
  418. 418.
    Savin R, Atton A, Bergstressor PR, et al. Efficacy of terbinafine 1% cream in the treatment of moccasin-type tinea pedis: results of placebo-controlled multicenter trials. J Am Acad Dermatol 1994; 30: 663–7PubMedCrossRefGoogle Scholar
  419. 419.
    Berman B, Ellis C, Leyden J, et al. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. J Am Acad Dermatol 1992;26: 956–60PubMedCrossRefGoogle Scholar
  420. 420.
    Evans EGV. A comparison of terbinafine (Lamisil) 1% cream given for one week with clotrimazole (Canesten) 1% cream given for four weeks, in the treatment of tinea pedis. Br J Dermatol 1994; 130: 12–4PubMedCrossRefGoogle Scholar
  421. 421.
    Evans EGV, Dodman B, Williamson DM, et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. BMJ 1993; 307: 645–7PubMedCrossRefGoogle Scholar
  422. 422.
    Bergstresser PR, Elewski B, Hanifin J, et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1- and 4-week treatment regimens. J Am Acad Dermatol 1993; 28: 648–51PubMedCrossRefGoogle Scholar
  423. 423.
    Elewski B, Bergstresser PR, Hanifin J, et al. Long-term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole. J Am Acad Dermatol 1995; 32: 290–2PubMedCrossRefGoogle Scholar
  424. 424.
    Ablon G, Rosens T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Clin Trials J 1996; 35(8): 591–3Google Scholar
  425. 425.
    Nolting S, Bräutigam M. Clinical relevance of the antibacterial activity of terbinafine: a contralateral comparison between 1% terbinafine cream and 0.1% gentamicin sulphate cream in pyoderma. Br J Dermatol 1992; 126 Suppl. 39: 56–60CrossRefGoogle Scholar
  426. 426.
    Greer DL, Jolly HW. Treatment of tinea cruris with topical terbinafine. J Am Acad Dermatol 1990; 23: 800–4PubMedCrossRefGoogle Scholar
  427. 427.
    Millikan LE. Efficacy and tolerability of topical terbinafine in the treatment of tinea cruris. J Am Acad Dermatol 1990; 23: 795–9PubMedCrossRefGoogle Scholar
  428. 428.
    Evans EGV, Shah JM, Joshipura RC. One-week treatment of tinea corporis and tinea cruris with terbinafine (Lamisil) 1% cream: a placebo-controlled study. J Dermatol Treat 1992; 3: 181–4CrossRefGoogle Scholar
  429. 429.
    Zaias N, Berman B, Cordera CN, et al. Efficacy of a 1-week, once-daily regimen of terbinafine 1% cream in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol 1993; 29: 646–8PubMedCrossRefGoogle Scholar
  430. 430.
    El-Mansy I, Halim S. Efficacy of one week terbinafine (Lamisil) 1% cream in the treatment of tinea cruris/corporis. Egypt J Dermatol Venereol 1994; 14(1): 99–104Google Scholar
  431. 431.
    Evans EGV, Seaman RAJ, James IGV Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections. Br J Dermatol 1994; 130: 83–7PubMedCrossRefGoogle Scholar
  432. 432.
    Meinhof W, Girardi RM, Stracke A. Patient noncompliance in dermatomycosis. Dermatologica 1984; 169 Suppl. 1: 57–66CrossRefGoogle Scholar
  433. 433.
    Cooke J. Pharmacoeconomics of antifungal therapy. Bone Marrow Transplant 1994; 14: 518–20Google Scholar
  434. 434.
    Einarson TR, Arikian SR, Shear NH. Pharmacoeconomic analysis of oral drugs in treatment of tinea infections. J Res Pharmaceut Econ 1995; 6(3): 15–37Google Scholar
  435. 435.
    Einarson TR, Arikian SR, Shear NH. Pharmacoeconomic analysis of oral treatments for onychomycosis: a Canadian study. J Res Pharmaceut Econ 1995; 6(1): 3–22CrossRefGoogle Scholar
  436. 436.
    Einarson TR, Arikian SR, Shear NH. Cost-effective analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130: 32–4PubMedCrossRefGoogle Scholar
  437. 437.
    Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130: 35–44PubMedCrossRefGoogle Scholar
  438. 438.
    Bergman W, Rutten FFH. Oral behandeling van onychomycose van de teennagels; vergelijking van kosteneffectiviteit van griseofulvine, itraconazol, ketoconazol en terbinafine. Ned Tijdschr Geneeskd 1994; 138: 2346–50PubMedGoogle Scholar
  439. 439.
    Einarson TR, Gupta AK, Shear NH, et al. Clinical and economic factors in the treatment of onychomycosis. Pharmacoeconomics 1996; 9: 307–20PubMedCrossRefGoogle Scholar
  440. 440.
    Halpern MT, Palmer C. Modeling the cost effectiveness of oral therapy for nail fungus. Am J Man Care 1996; 2: 59–66Google Scholar
  441. 441.
    Marchetti A, Piech CT, McGhan WF, et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18(4): 757–77PubMedCrossRefGoogle Scholar
  442. 442.
    Van Doorslaer EKA, Tormans G, Gupta AK, et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology 1996; 193: 239–44PubMedCrossRefGoogle Scholar
  443. 443.
    Einarson TR, Oh PI, Gupta AK, et al. Multinational pharmacoeconomic analysis of topical and oral therapies for onychomycosis. J Derm Treatment 1997; 8: 229–35CrossRefGoogle Scholar
  444. 444.
    Chren MM. Costs of therapy for dermatophyte infections. J Am Acad Dermatol 1994; 31: S103–6PubMedCrossRefGoogle Scholar
  445. 445.
    Chren MM, Landefeld S. A cost analysis of topical drug regimens for dermatophyte infections. JAMA 1994; 272: 1922–5PubMedCrossRefGoogle Scholar
  446. 446.
    Shear NH, Einarson TR, Arikian SR, et al. Pharmacoeconomic analysis of topical treatments for tinea infections. Pharmacoeconomics 1995; 7: 251–67PubMedCrossRefGoogle Scholar
  447. 447.
    Davis R, Balfour JA. Terbinafine: a pharmacoeconomic appraisal of its use in superficial fungal infections. Pharmacoeconomics 1995; 8: 1–12CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • Aditya K. Gupta
    • 1
  • Thomas R. Einarson
    • 2
  • Richard C. Summerbell
    • 3
  • Neil H. Shear
    • 4
  1. 1.Division of Dermatology, Department of MedicineSunnybrook Health Science Center, and the University of TorontoLondonCanada
  2. 2.Faculty of Pharmacy and Department of Health AdministrationUniversity of TorontoTorontoCanada
  3. 3.Ontario Ministry of Health, Laboratory Services Branch, and Department of Laboratory Medicine and PathobiologyUniversity of TorontoTorontoCanada
  4. 4.Divisions of Dermatology and Clinical Pharmacology, Department of MedicineSunnybrook Health Science Center, and the University of TorontoTorontoCanada

Personalised recommendations